DAFTAR PUSTAKA

Anonymous. 2015. Cardiovascular Disease. [internet], Available from: <http://www.who.int/mediacentre/factsheets/fs317/en/>. WHO.(Diakses tanggal 27 April 2015).

Baynes JW, Dominiczak MH. 2007. Medical Biochemistry. 2nd edition. Elsevier, London.

Connelly PW, Poapst M, Davignon J, Lussier-Cacan S, Reeder B, Lessard R, *et al*. 1999. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol 15(4):409-18.

Crawford MH. 2009. Current Diagnosis & Treatment: Cardiology. 3rd ed. McGraw-Hill Companies, USA.

Dawar R, Gurtoo A, Singh R. 2010. ApoB/apoA1 ratio is statistically the best predictor of myocardial infarction compared to other lipid ratios. IJPBS 1(2):1-8.

Dobiasova M, Frohlich J. 2000. The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy. Vnitr Lek 46(3):152-6.

Dobiasova M. 2006. AIP--Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 52(1):64-71.

Faqih DM, Paranadipa M, Trisna DV, Waluyo DA, Herqutanto, Ekayanti F, *et al*. 2013. Panduan Praktik Klinis Bagi Dokter di Fasilitas Pelayanan Kesehatan Primer. 1st edition. IDI, Jakarta.

Ferrara A, Barrett-Connor E, Shan J. 1997. Total, LDL, and HDL cholesterol decrease with age in older men and women the rancho bernardo study 1984–1994. Circulation 96:37-43.

Fuster V, Walsh RA, O'Rourke RA, Poole-Wilson P, Hurst's the Heart. 2011. 13th ed. McGraw-Hill Companies, USA.

Garfagnini A, Devoto G, Rosselli P, Boggiano P, Venturini M. 1995. Relationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery disease. Eur Heart J 16:465-70.

Gotto AM Jr. 2001. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease a working group report. Circulation 103:2213–18.

Hartopo AB, Gharini PPR, Hariawan H, Puspitawati I. 2013. Lipid aterogenik plasma sebagai prediktor kejadian buruk kardiovaskular selama perawatan penderita sindroma koroner akut. Laporan Penelitian. Fakultas Kedokteran, Yogyakarta.

James I, Cleeman. 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486-97.

Kaneva AM, Potolitsyna NN, Bojko ER, Odland JØ. 2015. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers 2015:591454.

Khadem-Ansari MH, Rasmi Y, Rahimi-Pour A, Jafarzadeh M. 2009. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. Singapore Med J 50(6):610

Khazaal MS. 2013. Atherogenic index of plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med 6(1):1506-13.

Kumar A. 2014. Correlation between anthropometric measurement, lipid profile, dietary vitamins, serum antioxidants, lipoprotein (a) and lipid peroxides in known cases of 345 elderly hypertensive South Asian aged 56-64 y-A hospital based study. Asian Pac J Trop Biomed. 4(Suppl1):S189-97.

Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. 1992. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men

and women with premature coronary artery disease. Am J Cardiol 69:1015–1021.

Lee DM, Alaupovic P. 1974. Composition and concentration of apolipoproteins in very-low- and low-density lipoproteins of normal human plasma. Atherosclerosis 19:501–20.

Lerner DJ, Kannel WB. 1986. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111(2):383-90.

Liberman, M, Mark’s AD, Smith C. 2007. Marks' Essential Medical Biochemistry. 2nd edition. Lippincott Williams & Wilkins, USA.

McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J. 2008. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEARTstudy): a case–control study. Lancet 72(9634):224–33.

Murray RK, Granner DK, Rodwell VW. 2006. Harper's Illustrated Biochemistry. 27th edition. McGraw-Hill, USA.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. J Am Med Assoc 290: 2292–300.

Schlitt A, Blankenberg S, Bickel C, Meyer J, Hafner G, Jiang XC, *et al*. 2005. Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 102: 477–85.

Soendoro T. 2008. Laporan hasil riset kesehatan dasar (RISKESDAS) nasional 2007. Badan Penelitian dan Pengembangan Kesehatan, Jakarta.

Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. 2003. Apolipoproteins versus lipids as indices of coronary risk and as target for statin treatment. Lancet 361(9359):777-80.

Tidy C, 2011. Apolipoprotein. 2011. [internet], Available from : <http://www.patient.co.uk/doctor/Apolipoproteins.htm> (Diakses tanggal 21 Agustus 2014).

Vance DE, Vance JE,. 2002. Biochemistry of Lipids, Lipoproteins and Membranes. 4th edition. Elsevier, London.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. Lancet 358:2026-33.

Walldius G, Jungner I. 2006. The ApoB/ApoA-I ratio: a strong, new risk factor for cardiovascular disease and a target

for lipid-lowering therapy– a review of the evidence. J Intern Med 259(5):493-519.

Wei Y, Qi B, Xu J, Shou G, Chen S, Ouyang P. 2014. Age- and sex-related difference in lipid profiles of patients hospitalized with acute myocardial infarction in East China. J Clin Lipodol 8:562-7

Willerson JT, Cohn JN, Wellens HJJ, Holmes DR Jr. 2007. Cardiovascular Medicine. 3rd ed. Springer, London.

Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Lanas F, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-52.